Important note: Information in this article was accurate in 2008. The state of the art may have changed since the publication date.
South African Press Association - June 26, 2008
Spokesperson Sibani Mngadi said the tender was awarded to support the implementation of the comprehensive response to HIV/Aids in South Africa.
"The prices were lower than in the last tender. The percentages decrease ranged from 20% to 71%. Only Efavirenz (one of the ARVs) has a sole supplier with an increase of 24%," he said.
The reduced prices were due to higher volumes, the entry of generic medicines on to the market and a more competitive climate.
The six suppliers were GlaxoSmithKline with 6,9%, Aspen Pharmacare with 56,8%, Adcock Ingram with 20,9%, MSD with 9,1%, Medpro with 1,9% and Sonke with 4,5%.
"The awarding of this tender once again demonstrates the continued commitment to expanding access to HIV and Aids related treatment," said Mngadi.
"We have to ensure that there is adequate and uninterrupted supply of the necessary medicine to the accredited treatment centres across the country."
According to the department, the South African government's ARV tender is the largest in the world.
"The accumulative number of patients initiated on ARVs was more than 478 000 by end of April 2008 which constitutes the highest number of people initiated on ARV treatment in any other country," he said.
Aspen, the supplier that won most of the tender, said the results reflected positively on competitiveness, breadth of product offering and on the effectiveness of service delivery.
Aspen chief executive Stephen Saad said the tender was effective for a period of two years, commencing retrospectively from June 1 2008.
In addition to maintaining the supply contract for existing tender items, Aspen had also secured volumes for two new products, Aspen Efavirenz and Tenofivir.
Aspen had been able to respond to this growth in demand, it said.
Products were manufactured at the company's facility in Port Elizabeth.
080626
SA080603
Copyright © 2008 - South African Press Association. Reproduction of this article (other than one copy for personal reference) must be cleared through the South African Press Association, Cotswold House, Greenacres Office Park, Cnr. Victory & Rustenburg Roads, VICTORY PARK, PO BOX 7766, JOHANNESBURG, 2000; Fax No: +27 11 782-1587/8, Tel No: +27 11 782-1600.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.
Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .